We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases / Novasep invests €10M to reinforce its bioconjugation services

Novasep invests €10M to reinforce its bioconjugation services

25 Jun 2015

Expansion marks Novasep’s readiness for full range Antibody Drug Conjugates CMO services

 Pompey, France, June 25, 2015 – Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

 The facility is planned to be commissioned in Q2 2016. It will provide contract manufacturing in batch sizes from a few milligrams to 600g to ADC drug developers during clinical trial and commercial development phases.

 “Combining chemistry and biology is not a given. Novasep is one of the few CMOs able to produce both commercial scale ADCs payloads and monoclonal antibodies,” said Thierry Van Nieuwenhove, president of Novasep’s Synthesis BU. “Customers are now searching for a simplified supply chain to produce their ADC and other bio-conjugate drug substances. By integrating our R&D, analytical and manufacturing services within a single unit, we can give customers flexibility, assurance of supply and continuity in supply chains.”

 Novasep’s €10M investment in clinical and commercial scale ADC conjugation is a natural extension to its existing CMO offering and leverages its unique purification technologies. Novasep’s new ADC facility, whose design is now complete, will be capable of producing ADCs in full compliance with the highest standards in quality, health, environmental and industrial safety.

 “This move is part of our “Back to basics” strategy, forging Novasep’s re-focus on growing core businesses,” said Dr Michel Spagnol, chairman and CEO of Novasep. “We are proud to see our Le Mans site continuing its growth in one of the pharmaceutical industry’s most exciting development areas.”


 About Novasep

Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.


Andrew Lloyd & Associates

Carol Leslie


UK and US: +44 1273 675 100

France: +33 1 56 54 07 00

Novasep Icon PDF  Novasep ADC invest - English version

Novasep Icon PDF Novasep ADC invest - German version

Novasep Icon PDF Novasep ADC invest - French version

Back to full list of events

You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback! .